Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer

Authors: Manijeh Mahdavi, Mehrnaz Keyhanfar, Abbas Jafarian, Hassan Mohabatkar, Mohammad Rabbani

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Because of direct stimulating immune system against disease, vaccination or active immunotherapy is preferable compared to passive immunotherapy. For this purpose, a newly designed chimeric peptide containing epitopes for both B and T cells from HER2 ECD subdomain III was proposed. To evaluate the effects of the active immunization, a discontinuous B cell epitope peptide was selected based on average antigenicity by bioinformatics analysis. The selected peptide was collinearly synthesized as a chimera with a T helper epitope from the protein sequence of measles virus fusion (208-302) using the GPSL linker. Three mice were immunized with the chimeric peptide. Reactive antibodies with HER2 protein in ELISA and immunofluorescence assays with no cross-reactivity were generated. The 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay indicated that the anti-peptide sera had inhibitory effects on proliferation of SK-BR-3 cells. Hence, the newly designed, discontinuous chimeric peptide representing B and T cell epitopes from subdomain III of HER2-ECD can form the basis for future vaccines design, where these data can be applied for monoclonal antibody production targeting the distinct epitope of HER2 receptor compared to the two broadly used anti-HER2 monoclonal antibodies, Herceptin and pertuzumab.
Literature
1.
Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res. 2001;3:399–403.PubMedPubMedCentral
2.
Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343–57.PubMed
3.
Jager D, Knuth A. Antibodies and vaccines—hope or illusion? Breast. 2005;14:631–5.PubMed
4.
Milani A, Sangiolo D, Montemurro F, Aglietta M, et al. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013;24(7):1740–8.PubMed
5.
Garrett JT, Kaumaya P, Pei D, Dalbey R et al (2007). Peptide based B cell epitope vaccines targeting HER-2/Neu. Dissertation, Ohio State University
6.
Ladjemi MZ, Jacot W, Pèlegrin A, Navarro-Teulon I. Vaccination anti-HER2: l’avenir du ciblage immunologique de HER2? Review Article. Pathol Biol. 2011;59:173–82.PubMed
7.
Dakappagari NK, Pyles J, Parihar R, Carson WE, et al. Multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumour responses. J Immunol. 2003;170:4242–53.PubMed
8.
Milich DR. Synthetic T and B cell recognition sites: implications for vaccine development. Adv Immunol. 1989;45:195–282.PubMed
9.
Gangwara RS, Shil P, Sapkala GN, Khanc SA, et al. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes. Vir Res. 2012;163:40–50.
10.
Miyako H, Kametani Y, Katano I, Ito R, et al. Antitumor effect of New HER2 peptide vaccination based on B cell epitope. Anticancer Res. 2011;31:3361–8.PubMed
11.
Mahdavi M, Mohabatkar H, Keyhanfar M, Jafarian Dehkordi A, et al. Linear and conformational B cell epitope prediction of HER 2 ECD-subdomain III by in silico methods. Asian Pac J Cancer Prev. 2012;13:3053–9.PubMed
12.
Mahdavi M, Keyhanfar M, Moreau V, Mohabatkar H, et al. In silico design of discontinuous peptides representative of B and T-cell epitopes from HER2-ECD as potential novel cancer peptide vaccines. Asian Pac J Cancer Prev. 2013;14:5973–81.
13.
Jasinska J, Wagner S, Radauer C, Sedivy R, et al. Inhibition of tumour cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of HER-2/Neu. Int J Cancer. 2003;107:976–83.PubMed
14.
Zhang AL, Xue H, Ling XG, Gao Y, et al. Anti-HER-2 engineering antibody ChA21 inhibits growth and induces apoptosis of SK-OV-3 cells. J Exp Clin Cancer Res. 2010;29:23–32.PubMedPubMedCentral
15.
Kaumaya PTP, Kobs-Conrad S, DiGeorge AM, Stevens V. De novo engineering of protein immunogenic and antigenic determinants. In: Anantharamaiah GM, Basava C, editors. Peptides, design, synthesis & biological activity. Boston: Birkhauser; 1994. p. 133–64.
16.
Kaumaya PTP. Synthetic peptide vaccines: dream or reality. In: Schneider CH, editor. Peptides in immunology. United Kingdom: Wiley; 1996. p. 117–48.
17.
Partidos CD, Steward MW. Prediction and identification of a T cell epitope in the fusion protein of measles virus immunodominant in mice and humans. J Gen Virol. 1990;71:2099–105.PubMed
18.
Maupetit J, Derreumaux P, Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. 2009;37:498–503.
19.
DeLano WL. The PyMOL molecular graphics system. San Carlos: DeLano Scientific; 2002.
20.
Scott WRP, Hünenberger PH, Tironi IG, Mark AE, et al. The GROMOS biomolecular simulation program package. J Phys Chem A. 1999;103:3596–607.
21.
Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis. 1997;18:2714–23.PubMed
22.
Yokoyama WM (1995) Production of monoclonal antibodies. In: Current Protocols in Immunology, John Wiley & Sonc
23.
Tabll A, Khalil SB, El-Shenawy RM, Esmat G, et al. Establishment of hybrid cell lines producing monoclonal antibodies to a synthetic peptide from the E1 region of the hepatitis C virus. J Immunoass Immunochem. 2007;29:91–104.
24.
Hornbeck P (1991) Enzyme-linked immunosorbent assays. In: Current Protocols in Immunology, John Wiley & Sonc
25.
Larry M, Lantz BJ, Fowlkes IS, Janis VG (2001) Preparation of cells and reagents for flow cytometry. In: Current Protocols in Immunology, Wiley
26.
Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990;276:172–4.PubMed
27.
Deulofeut H, Iglesias A, Mikael N, Bing DH, et al. Cellular recognition and HLA restriction of a midsequence HBsAg peptide in hepatitis B vaccinated individuals. Mol Immunol. 1993;30:941–8.PubMed
28.
Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, et al. Prevention of mammary tumours with a chimeric Her-2 B-cell epitope peptide vaccine. Cancer Res. 2000;60:3782–9.PubMed
29.
Wang B, Kaumaya PTP, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gyn Oncol. 2010;119:564–70.
30.
Sundaram R, Lynch MP, Rawale SV, Sun Y, et al. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem. 2004;279:141–51.
31.
Boyer CM, Pusztai L, Wiener JR, Xu FJ, et al. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer. 1999;82:525–31.PubMed
32.
Wang JN, Feng JN, Yua M, Xua M, et al. Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitor monoclonal antibodies. Mol Immunol. 2004;40:963–9.PubMed
33.
Zhang W, Xiong Y, Zhao M, Zou H, et al. Prediction of conformational B-cell epitopes from 3D structures by random forests with a distance-based feature. BMC Bioinform. 2011;12:341–8.
34.
Siyi H, Zhiqiang Z, Liangwei L, Liang C, et al. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: molecular basis for tumour inhibitory mechanism. Proteins. 2008;70:938–49.
35.
Haro I, Gomara MJ. Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr Protein Pept Sci. 2004;5:425–33.PubMed
36.
Aguilar RM, Talamantes FJ, Bustamante J, Muñoz J, Treviño LR, et al. Multiple antigen peptide dendrimer elicits antibodies for detecting rat and mouse growth hormone binding proteins. J Pept Sci. 2009;15:78–88.PubMedPubMedCentral
37.
Jalali A, Sankian M, Tavakkol-Afshari J, Jaafari MR. Induction of tumour-specific immunity by multi-epitope rat HER2/neu-derived peptides encapsulated in LPD Nanoparticles. Nanomed Nanotech Biol Med. 2012;8:692–701.
38.
Singh R, Rothman AL, Potts J, Guirakhoo F, et al. Sequential immunization with heterologous chimeric flaviviruses induces broad-spectrum cross-reactive CD8+ T cell responses. J Infect Dis. 2010;202:223–33.PubMed
39.
Axelsena TV, Holma A, Christiansena G, Birkelund S. Identification of the shortest AB-peptide generating highly specific antibodies against the C-terminal end of amyloid-B42. Vaccine. 2011;29:3260–9.
40.
Ripoll DR. Conformational study of a peptide epitope shows large preferences for beta-turn conformations. Int J Pept Protein Res. 1992;40:575–81.PubMed
41.
Dakappagari NK, Lute KD, Rawale S, Steele JT, et al. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumour cell binding and antitumour activities. J Biol Chem. 2005;280:54–63.PubMed
42.
Chen SW, Van Regenmortel MH, Pellequer JL. Structure-activity relationships in peptide-antibody complexes: implications for epitope prediction and development of synthetic peptide vaccines. Curr Med Chem. 2009;16:953–9.PubMed
43.
Yarden Y, Peles E. Biochemical analysis of the ligand for the neu oncogenic receptor. Biochem. 1991;30:3543–50.
44.
Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamon D, et al. Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Sci. 1990;249:1552–5.
45.
Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA. 1991;88:8691–5.PubMedPubMedCentral
46.
Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci U S A. 1995;92:3353–7.PubMedPubMedCentral
47.
Courtenay-Luck NS, Epenetos AA, Moore R, Larche M, Pectasides D, Dhokia B, et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res. 1986;46(12 Pt 1):6489–93.PubMed
Metadata
Title
Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer
Authors
Manijeh Mahdavi
Mehrnaz Keyhanfar
Abbas Jafarian
Hassan Mohabatkar
Mohammad Rabbani
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2503-y

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

Correlation between expression of thymidylate synthase and clinical outcome of advanced gastric cancer treated with capecitabine alone chemotherapy

Research Article

C-Myc-activated long noncoding RNA CCAT1 promotes colon cancer cell proliferation and invasion

Research Article

Meta-analysis of studies on the association between the NF-κB1-94ins/del ATTG promoter polymorphism and cancer

Research Article

Somatic mutations of the HER2 in metastatic breast cancer

Research Article

Overexpression of GOLPH3 protein is associated with worse prognosis in patients with epithelial ovarian cancer

Research Article

SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits